Stereotactic Ablative Radiotherapy with CyberKnife for Advanced Thymic Carcinoma: A Case Report

Fan, Chao-Yueh; Huang, Wen‐Yen; Jen, Yee‐Min; Lin, Meng‐Chih; Lin, Kuen‐Tze

doi:10.3747/co.22.2693

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, only five literatures have reported 19 cases of SBRT for thymoma, and the most of these reports are case reports 13 , 15 , 16 . This is the first cohort study investigating the use of SBRT for treatment of patients with thymic tumors.…”

Section: Discussionmentioning

confidence: 99%

Prospective Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment

Hao

Peng

Zhou

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Stereotactic body radiation therapy (SBRT) is an important modality in treatment of tumors. We hypothesized that SBRT can achieve excellent local control with limited toxicity in patients with thymic tumors. A single-institution prospective study was performed with 32 patients who underwent SBRT of thymoma and thymic carcinoma between 2005 and 2014. Thirty-two patients including 39 target lesions were analyses in this study. Almost half of the patients (46.9%) were type C by histopathology and more than half (56.3%) were classified into stage IVA or IVB. The median dose of SBRT for gross tumor volume (GTV) was 56 Gy (range 49–70 Gy). Results showed that the response rate was 96.9% after SBRT and the median tumor shrinkage rate was 62.2% (range 3.8–100%). For the patients with both stage II–III and type A-B (n = 6), the median PFS was 28 months. In-field failure was only observed in 4 patients, and outside-field failure was seen in 2 patients. The local control rate was 81.25%. Patients treated with SBRT had an excellent local control with mild toxicities, which suggests that SBRT is feasible for the patients with thymic tumors who are unable to undergo either surgery or conventionally fractionated radiation therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment

Hao

Peng

Zhou

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Fan, et al reported the first instance of CyberKnife stereotactic ablative radiotherapy for Stage IVa thymic carcinoma [8]. Their case was successful with no recurrence and no radiation toxicity at 72 months’ follow-up.…”

Section: Discussionmentioning

confidence: 99%

“…In the clinical analysis of 45 patients, the three-year survival rate was 59.4% in patients treated with conventional radiotherapy and 80% in those treated with stereotactic body radiotherapy (SBRT) [7]. In the literature, there is only one case report of SBRT with CyberKnife (Accuray, Sunnyvale, CA, USA) [8]. Here, we report our experience of SBRT with CyberKnife for 10 cases of advanced thymic carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy

Harada¹,

Miyazaki²

2017

Cureus

View full text Add to dashboard Cite

The standard treatment for advanced thymic carcinoma has not yet been established. Most patients have no symptoms until the advanced stage. Radiation therapy has been used for advanced stage cancer, usually in combination with surgery or chemotherapy; however, the survival rates are 30%-50%. We performed hypofractionated stereotactic radiotherapy with CyberKnife (Accuray, Sunnyvale, CA, USA) for 10 cases of advanced thymic cancer. All cases reached at least partial remission (PR) in two months with progression-free irradiated lesions and minimal radiation-related toxicity. It took only seven to 12 days for each therapy that did not require admission. CyberKnife is beneficial for patients even at the terminal stage.

show abstract